Hartmut Ehrlich, Abivax CEO
French startup Abivax raises $49M to cross the PhIII finish line for ulcerative colitis drug
To keep its boat sailing in the current biotech market, the French biotech Abivax has put together some new cash.
Most of the net proceeds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
